A subsidiary of Mallinckrodt will commence a cash tender offer to purchase all outstanding shares of Ocera
Therapeutics common stock for USD 1.52 per share (approximately USD 42m), plus one contingent value right to receive one or more payments in cash of up to USD 2.58 per share (up to approximately USD 75m) based on the successful completion of certain development and sales milestones.
12 December 2017 - UK-based specialty pharmaceutical company Mallinckrodt plc (NYSE: MNK) has closed the acquisition of California, US-based biopharmaceutical company Ocera
For example, the $28 million placement for Ocera
Therapeutics provided the firm with sufficient funding to advance OCR-002, developed for the treatment of hepatic encephalopathy, through the phase 2b study.
Chang has received consulting fees from Albireo, GlaxoSmithKline, McNeil Pharmaceuticals, Ocera
Therapeutics, Prometheus Laboratories, Rose Pharmaceuticals, Salix Pharmaceuticals, and Takeda Pharmaceutical Co., as well as salary and grant/research support from Prometheus, Rose, and Takeda.
(14.) Macias EA, Mason EO Jr, Ocera
HY, La Rocco MT.
HY, LaRocco MT Comparison of E test with standard broth microdilution for determining antibiotic susceptibilities of penicillin-resistant strains of Streptococcus pneumoniae.
She also served as chief financial officer of Symyx Technologies, a research services, software and instrumentation company, Ocera
, a biopharmaceutical company, and Cytel, an immunotherapy company.
M2 EQUITYBITES-November 6, 2017-Mallinckrodt to Acquire Ocera
Therapeutics to Expand Treatments in Liver Disease
Mallinckrodt plc, a leading global specialty pharmaceutical company, and Ocera
Therapeutics, Inc., today announced that they have entered into an agreement under which Mallinckrodt will acquire Ocera
, a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for orphan and other serious liver diseases with high unmet medical need.
Therapeutics Inc (NASDAQ: OCRX) shares jumped 68.5 percent to $1.68 after the company agreed to be acquired by Mallinckrodt PLC (NYSE:MNK) for $1.52 per share.
Hoffmann-La Roche Ltd., Novartis AG, Conatus Pharmaceuticals Inc., Valeant Pharmaceuticals International, Inc., Ocera
Therapeutics, Inc., Norgine B.V., GlaxoSmithKline Plc, C.
Companies Mentioned in this Report: Atlantic Healthcare Plc, Ocera
Therapeutics, Inc., FORMAC Pharmaceuticals N.V., Ospedali Riuniti di Bergamo, Baxalta Incorporated, AesRx, LLC., AbbVie Inc."